A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma
Status:
Not yet recruiting
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose
escalation,optimization, and expansion study of tegavivint in patients with advanced HCC
after failure of at least one line of prior systemic therapy. In the second part of the
study, the combination of tegavivint plus pembrolizumab will be assessed with a limited dose
escalation followed by a randomized dose optimization.